[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$hlubf
$HLUBF sees a surge in creator activity with positive news from Praxis. Engagements are high, driven by the FDA Breakthrough Therapy Designation.
About $hlubf
A cryptocurrency asset.
Insights #
- $hlubf creators is up XXX% from the previous week.
- $hlubf Creators hit a high of X for the day
- $hlubf Creators hit an all time of X for the day
- $hlubf Engagements hit a high of XXXXX for the day
- $hlubf Engagements hit an all time of XXXXX for the day
Engagements: XXX #
Engagements 24-Hour Chart Data
Current Value: XXX
Daily Average: XX
1 Month: XXXXX +125%
1-Year High: XXXXX on 2025-07-18
1-Year Low: X on 2025-05-01
| Social Network | X |
|---|---|
| Engagements | XXX |
Mentions: X #
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: X no change
1 Month: X +50%
1-Year High: X on 2025-04-29
1-Year Low: X on 2025-05-01
| Social Network | X |
|---|---|
| Mentions | X |
Creators: X #
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning $hlubf in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
1 Week: X +100%
1 Month: X +100%
1-Year High: X on 2025-07-18
1-Year Low: X on 2025-04-29
Top assets mentioned In the posts about $hlubf in the last XX hours
Top topics mentioned In the posts about $hlubf in the last XX hours
$ucbjf, $biib, $aqst, nyc, investment, brt, $snnuf, $aoiff, $olp, $skfof
Top Social Posts #
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG $NBIX ( $LBPH - $HLBBF $HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed"
@Quantumup1 on X 2025-07-18 12:42:09 UTC 3519 followers, 1325 engagements